FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...
Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.
Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA ...
The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked ...
US FDA approves Vanda Pharma’s Nereus, an oral NK-1 receptor antagonist for prevention of vomiting induced by motion: Washington Friday, January 2, 2026, 15:00 Hrs [IST] Vanda P ...
Pharmaceutical Technology on MSN
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback